Bicara Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Bicara Therapeutics Inc. (BCAX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$324.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- Bicara Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$324.00K.
- Bicara Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$486.00K.
- Bicara Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $379.00K.
- Bicara Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$136.00K.
- Bicara Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $243.00K.
- Bicara Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $0.00.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$324.00K 10-Q · filed 2026-08-11 | -$810.00K 10-Q · filed 2026-08-11 | -$431.00K derived: sum of 3 quarters · filed 2026-08-11 | -$567.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$486.00K 10-Q · filed 2026-05-11 | -$107.00K derived: sum of 2 quarters · filed 2026-05-11 | -$243.00K derived: sum of 3 quarters · filed 2026-05-11 | -$243.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $379.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $243.00K derived: sum of 2 quarters · filed 2026-03-30 | $243.00K derived: sum of 3 quarters · filed 2026-08-11 | $243.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$136.00K 10-Q · filed 2025-11-10 | -$136.00K derived: sum of 2 quarters · filed 2026-08-11 | -$136.00K 10-Q · filed 2025-11-10 | -$136.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |